Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. (PHVS) director Robert Howard Glassman filed a Rule 144 notice indicating an intention to sell up to 14,493 shares of Pharvaris common stock through Morgan Stanley Smith Barney LLC on September 17, 2026. The shares relate to a stock option exercise with cash payment.
The notice also lists prior sales by Robert Glassman over the preceding three months, including 8,667 and 8,000 Pharvaris common shares sold on September 15 and September 9, 2026, respectively.
Pharvaris N.V. (PHVS) reported that Chief Technical Ops Officer Stefan Andreas Abele exercised stock options for 45,000 shares of common stock at an exercise price of $16.40 per share on September 15, 2026, leaving 44,500 options outstanding from that grant. The acquired shares were largely sold the same day in a cashless exercise, including 45,000 shares at a weighted average price of $38.1375 per share and 1,400 shares at a weighted average price of $39.2411 per share, with prices in each sale reported as ranges. No Rule 10b5-1 trading plan is indicated.
Pharvaris N.V. (PHVS) director Robert Glassman reported a cashless exercise and sale of stock options on September 15, 2026. He exercised options for 8,667 shares of common stock at an exercise price of $22.31 per share and sold the same 8,667 shares at a weighted average price of $38.2735 per share, with individual sale prices ranging from $38.175 to $38.43. The option, which expires April 11, 2034, was fully exercised in this transaction, and the transactions were made under a Rule 10b5-1 trading plan.
Pharvaris N.V. (PHVS) reported that Chief Commercial Officer Wim Souverijns exercised options and sold shares in mid-September 2026 under a Rule 10b5-1 trading plan. On September 14, 2026, he exercised options for 20,000 shares at $17.43 per share and immediately sold 20,000 shares in a cashless exercise at a weighted average price of $39.31. On September 15, 2026, he separately sold 6,090 shares at $38.99 per share, also under a Rule 10b5-1 plan. Following the option exercise, 95,000 options from that grant remained outstanding.
Pharvaris N.V. (PHVS) is named as the issuer in a notice that Stefan Andreas Abele, an officer, may sell up to 46,400 common shares under Rule 144 through Morgan Stanley Smith Barney LLC on or after September 15, 2026 on NASDAQ. The shares include 45,000 shares from a stock option exercise dated September 15, 2026 and a total of 1,400 restricted stock shares from grants dated June 8, 9, 11, 12, 2026 and August 11, 2026.
Pharvaris N.V. (PHVS) reports that director Robert Howard Glassman has filed a notice to sell Pharvaris common shares under Rule 144. The planned sale covers 8,667 common shares, expected to be sold on September 15, 2026, in connection with a stock option exercise for cash through Morgan Stanley Smith Barney LLC.
The notice also lists a prior sale by Robert R. Glassman of 8,000 common shares on September 9, 2026 for total proceeds of $300,396.00.
Pharvaris N.V. (PHVS) reported that its President, Lu Peng, executed an options-related transaction and associated share dispositions. On September 11, 2026, Lu Peng exercised stock options to acquire 15,000 shares of common stock at an exercise price of $2.59 per share and, in connection with a cashless exercise pursuant to a Rule 10b5-1 trading plan, sold 15,000 shares at a weighted average price of $40.1298 per share, with sale prices ranging from $40.00 to $40.30.
In addition, the issuer withheld 109 shares on September 11, 2026, and 117 shares on September 14, 2026, to satisfy tax withholding obligations upon the vesting of restricted stock units. Following these transactions, Lu Peng continues to hold stock options with an exercise price of $2.59 per share for underlying 15,000 shares of common stock, expiring on February 3, 2030, with 13,308 options reported as outstanding after the exercise.
Pharvaris N.V. (PHVS) director and Chief Executive Officer Berndt Modig reported selling 2,291 shares of Common Stock on September 14, 2026 at a weighted average price of $39.40 per share in open-market transactions under a Rule 10b5-1 trading plan. The sale followed vesting of restricted stock units and a cashless exercise of stock options. After the sale, he held 128,334 shares directly and 950,000 shares indirectly through Schoodic Management BV, an entity he controls.
Pharvaris N.V. (PHVS) has an officer, Wim Souverijns, filing a notice of proposed sale of company common shares under Rule 144. The filing covers up to 26,090 shares of Pharvaris common stock to be sold through Morgan Stanley Smith Barney LLC, with a stated aggregate market value of $1,023,583.19 as of September 14, 2026 on NASDAQ. The shares consist of 6,090 restricted stock acquired from the issuer upon vesting between March 12 and August 12, 2026 and 20,000 shares issuable from a stock option exercise dated September 14, 2026.
Pharvaris N.V. (PHVS) is the issuer of common shares that Berndt B.A.E. Modig has notified for potential resale under Rule 144. The notice covers 2,291 common shares, held through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of $87,103.82 and a proposed sale date of September 14, 2026 on NASDAQ.
The shares were acquired from the issuer upon vesting of restricted stock units during the period of September 11–12, 2026. The notice also lists prior 10b5-1 plan sales over the past three months, each involving roughly 2,291–2,292 shares of Pharvaris common stock.